Research library

B

grade

GLP-1 receptor agonists may be associated with lower rates of gastrointestinal symptoms in IBS patients, but further prospective studies are needed to confirm these findings.

8.9% chronic diarrhea vs 10.6% in non-GLP-1 group at 90 days, p<0.001.

summary

B

grade

GLP-1RA use may be linked to a lower chance of starting antidepressants and medications for substance use disorder, but further research is needed to understand these associations better.

GLP-1RA initiation inversely associated with antidepressants (aSR: 0.85; 95% CI: 0.76-0.94)

summary

A

grade

Adding semaglutide to dose-reduced insulin glargine improves glycaemic control and reduces weight in type 2 diabetes, but watch for gastrointestinal side effects.

ETD for HbA1c reduction: -0.74%; CI95: -0.90, -0.59

summary

B

grade

Icodec may be a cost-effective option for type 2 diabetes management in Italy, offering improved quality-adjusted life expectancy with less frequent dosing.

0.16 QALYs gained with icodec versus glargine U100 and degludec.

summary

B

grade

SGLT2 inhibitors may protect kidney function in elderly diabetic patients but increase genital infection risk. Consider patient characteristics when prescribing.

HR 0.69 for 30% eGFR decline, 95% CI 0.59-0.80, p<0.001

summary

D

grade

Mazdutide may offer better glycemic control and weight loss compared to dulaglutide, but it also comes with a higher incidence of gastrointestinal side effects.

−0.25% HbA1c mean difference vs dulaglutide, 95% CI −0.38 to −0.12, p=0.0002

summary

C

grade

Dulaglutide appears to reduce liver injury markers in a mouse model of metabolic dysfunction-associated steatotic liver disease, but further research is needed to confirm its relevance in humans.

Not reported in abstract.

summary

B

grade

Biosimilars like Cyltezo and Avsola offer better clinical outcomes at much lower costs than their reference biologics, yet their formulary placement often does not reflect this value.

$6600 vs $107,992.82, yielding an ICER of -$2.25 million.

summary

A

grade

GLP-1 agonists may improve erectile dysfunction and increase certain hormone levels in males, but larger studies are needed to confirm these effects.

MD = 2.73 improvement in ED score, 95% CI: 1.64-3.83

summary

A

grade

Insulin glargine did not show significant benefits over usual care in terms of time in very low range or target range for children and young adults with type 1 diabetes in low-resource settings.

Adjusted mean difference for time in very low range was 0.22% (97.5% CI -0.83 to 1.27, p=0.63).

summary

D

grade

GLP-1RAs show potential for metabolic benefits in MS patients, but no significant changes in neurological outcomes were observed. Further randomized controlled trials are necessary to clarify these findings.

7.4% ever-use of GLP-1RAs reported in a NARCOMS survey (n=4181).

summary

D

grade

Imbalances in baseline hazards can occur in about 0.3% of large trials, potentially misrepresenting the intervention's true effect.

In a median of 3 (IQR 2, 4) of 1000 randomisations (0.3%), the hazard ratio for death was < 0.85 or > 1.18 by chance alone.

summary

C

grade

BiP overexpression in CHO cells can increase the final titer of dulaglutide production by 40% without affecting cell viability.

40% higher final titer in DUL-BiP cells compared to DUL-Neo controls.

summary

D

grade

Not reported in abstract.

summary

A

grade

Baseline NT-proBNP and cTnI are strong prognostic markers for adverse cardiovascular outcomes in type 2 diabetes patients, with significant increases over one year indicating higher risk.

Adjusted HR per 1 integer unit of baseline NT-proBNP for MACE was 1.63, P < .001.

summary

B

grade

Virtual shared medical appointments may help increase GLP-1 medication dosage and support weight loss in engaged patients, but the findings should be interpreted with caution due to the study's limitations.

Weight decreased from 227 lb (53 lb) to 211 lb (46 lb), n=17.

summary

B

grade

Pediatric obesity management shows considerable variability among clinics, highlighting the need for standardized care models to improve treatment consistency.

Not reported in abstract.

summary

B

grade

The study highlights that using composite endpoints can provide a more comprehensive understanding of the value of treatments like dulaglutide, with NNTs of 72 for MACE-3 and CPEA of $1,884,013.

$1,884,013 for CPEA of dulaglutide MACE-3

summary

A

grade

GLP-1 receptor agonists may reduce major kidney and cardiovascular events in CKD patients with type 2 diabetes, but they are associated with significant gastrointestinal side effects.

RR for all-cause mortality was 0.83; 95% CI, 0.76-0.90.

summary

B

grade

Clinicians should be aware that severe adverse reactions to piperacillin/tazobactam can occur, even shortly after administration, and should monitor patients closely.

Not reported in abstract.

summary